Company intelligence / Profile preview

Bird Rock Bio

La Jolla, California, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~3
Development stage: Phase 2

Overview

Bird Rock Bio completed a Phase 1b multiple ascending dose trial for nimacimab in patients with non-alcoholic fatty liver disease (NAFLD) and diabetes or pre-diabetes. The trial showed no serious adverse events or early terminations due to adverse events. The company's lead candidate gerilimzumab (anti-IL-6 antibody) demonstrated safety and pharmacokinetics supporting low, infrequent dosing in clinical trials.

Therapeutic areas: GastroenterologyMetabolic DisordersNephrologyImmunologyRare Diseases
Modalities: Monoclonal antibodiesNegative allosteric modulating antibody (NAMA)
Industry: Biotech

Drug pipeline

1 asset

namacizumab

Phase 2

Indications: Obesity, Metabolic disorders

Partnerships

Janssen Pharmaceuticals, Inc.GE HealthcareargenxGenor Biopharma

Beyond the preview

Go deeper on Bird Rock Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bird Rock Bio.

Explore the full profile